Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

bayer ab* - norethisteronum inn - tafla - 5 mg

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf. - acidum clavulanicum kalíum; amoxicillinum tríhýdrat - filmuhúðuð tafla - 875/125 mg

Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - brjóstakrabbamein - innkirtla meðferð - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.